Login
Israel-Hamas Conflict
Memorial Day
Cannes Film Festival
Accident
Social Media
Premier League
Drones
Disney
Baseball
US Politics
Wrestling
World Cup
Manchester United
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

HHS Policy Shift Could Boost Role of Patient Advocates in Clinical Trials

Summary by Pharmaceutical Commerce
Bruce Leuchter, CEO, Neurvati, discusses the indispensable role of patient advocates—particularly in rare and serious disease drug development—in shaping trial design, site selection, and regulatory strategy.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Pharmaceutical CommercePharmaceutical Commerce

HHS Policy Shift Could Boost Role of Patient Advocates in Clinical Trials

Bruce Leuchter, CEO, Neurvati, discusses the indispensable role of patient advocates—particularly in rare and serious disease drug development—in shaping trial design, site selection, and regulatory strategy.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pharmaceutical Commerce broke the news in on Friday, May 23, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal